- Home
- EUDA vs GNLX Comparison
EUDA vs GNLX Comparison
Compare EUDA & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EUDA
- GNLX
- Stock Information
- Founded
- EUDA 2021
- GNLX 2001
- Country
- EUDA Singapore
- GNLX United States
- Employees
- EUDA N/A
- GNLX N/A
- Industry
- EUDA Blank Checks
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- EUDA Finance
- GNLX Health Care
- Exchange
- EUDA Nasdaq
- GNLX Nasdaq
- Market Cap
- EUDA 111.5M
- GNLX 128.0M
- IPO Year
- EUDA N/A
- GNLX 2023
- Fundamental
- Price
- EUDA $1.48
- GNLX $3.56
- Analyst Decision
- EUDA
- GNLX Strong Buy
- Analyst Count
- EUDA 0
- GNLX 4
- Target Price
- EUDA N/A
- GNLX $17.75
- AVG Volume (30 Days)
- EUDA 84.3K
- GNLX 109.1K
- Earning Date
- EUDA 01-01-0001
- GNLX 08-07-2025
- Dividend Yield
- EUDA N/A
- GNLX N/A
- EPS Growth
- EUDA N/A
- GNLX N/A
- EPS
- EUDA N/A
- GNLX N/A
- Revenue
- EUDA $4,011,005.00
- GNLX N/A
- Revenue This Year
- EUDA $212.19
- GNLX N/A
- Revenue Next Year
- EUDA $254.35
- GNLX N/A
- P/E Ratio
- EUDA N/A
- GNLX N/A
- Revenue Growth
- EUDA 8.22
- GNLX N/A
- 52 Week Low
- EUDA $1.43
- GNLX $1.95
- 52 Week High
- EUDA $6.30
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- EUDA 26.11
- GNLX 53.81
- Support Level
- EUDA $1.43
- GNLX $3.26
- Resistance Level
- EUDA $2.71
- GNLX $3.61
- Average True Range (ATR)
- EUDA 0.30
- GNLX 0.23
- MACD
- EUDA -0.07
- GNLX -0.01
- Stochastic Oscillator
- EUDA 2.75
- GNLX 37.20
About EUDA EUDA Health Holdings Limited
EUDA Health Holdings Ltd is a non-invasive healthcare company across Southeast Asia and China. The Company has two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include common area property management services that contain cleaning, landscaping, public facilities maintenance and other traditional services and also include security property management services provided to all tenants and property owners.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.